输血患者直接抗人球蛋白试验阳性结果病种分布情况分析

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (996 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the disease distribution in blood transfusion patients with positive results of direct antiglobulin test (DAT). Methods The DAT test results and clinical data of 1609 blood transfusion patients in the Department of Transfusion Medicine of General Hospital of PLA Northern Theater from March 2010 to April 2022 were retrospectively analyzed, the relationship between different types of diseases and test results was explored, then the composition ratio of DAT positive patients and the changes in Hb, RBC, and Hct before and after red blood cell transfusions between the DAT positive group and the DAT negative group were investigated, so as to compare the efficiency of red blood cell transfusion between the DAT positive group and the DAT negative group. Results Of the 1609 cases, 1113 were DAT negative and 496 were DAT positive. Among 496 DAT-positive patients, rheumatic immunity-related diseases accounted for the highest proportion at 71.17%,and hematologic diseases followed at 13.91%. Among rheumatic-immunity-related diseases, the connective tissue disease (21.57%) and systemic lupus erythematosus (19.56%) accounted for the highest proportion; among hematologic diseases, thrombocytopenia (3.83%) and anemia (3.02%) accounted for the highest proportion. There was no significant difference in Hb, RBC, or Hct between the two groups before and after red blood cell infusion. The effective rate of red blood cell transfusion was 57.89% in DAT positive group and 78.95% in DAT negative group,and the difference between the two groups was statistically significant (P<0.05). Conclusions DAT is of great significance in clinically determining the nature of disease and accurate blood transfusion.

Key words： direct antiglobulin test rheumatic immunity-related disease blood incompatibility

Received: 11 May 2023

ZTFLH:

R457.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Dan
	LIU Jing
	ZHANG Jingrui
	ZHENG Wei

Cite this article:

ZHANG Dan,LIU Jing,ZHANG Jingrui等. Analysis of disease distribution in blood transfusion patients with positive results of direct antiglobulin test[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(12): 1030-1033.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I12/1030

[1]	徐爱芳,王妙婵,崔怀中.获得性免疫缺陷综合征患者直接抗人球蛋白试验检测的临床意义[J].中华检验医学杂志,2016,39(12):967-968.
[2]	临床输血规范流程协作组,李志强.临床输血适应性与有效性评价流程[J].中国输血杂志,2013,26(6) :587-589.
[3]	胡丽华.临床输血检验[M].2版.北京:中国医药科技出版社,2010:59-63.
[4]	贾冰,乔世岩.输血前不规则抗体筛查及直接抗人球蛋白试验的临床价值分析[J].中国实用医药,2022,17(14):85-87.
[5]	黄文娟,刘不尽.静脉注射人免疫球蛋白对输血相容性试验的影响[J].检验医学与临床,2022,19(13):1778-1780.
[6]	刘燕明,郭文敬,宫济武.微柱凝集技术检测直接抗人球蛋白试验结果分析[J].中国医药,2012,7(10):1282-1283.
[7]	张静,刘婷婷,李平. 86 例直接抗人球蛋白试验阳性病例分析[J].当代医学,2019,25(7):66-68.
[8]	康晓珍,彭炜童,魏寿忠.直接抗人球蛋白试验阳性分型与输血疗效关系探讨[J].临床输血与检验,2022,24(3):339-340.
[9]	宋倩,马怡然.自身抗体阳性致配血不相合红细胞输注疗效分析[J].临床输血与检验,2022,24(5):590.
[10]	胡建华,刘龙燕.微柱凝胶法交叉配血试验在临床输血中的应用[J].武警医学,2008,11(19):1049-1050.
[11]	刘凤霞,黄蓉,王勇军.自身抗体干扰输血相容性检测处理对策[J].中国输血杂志,2021,34(8) :803-808.
[12]	王艳军,赵润玲.外周血中性粒细胞／淋巴细胞比值及其与成分输血不良反应的关系[J].武警医学,2022,33(2):104.
[13]	李丹,王琳.抗Ce抗体及直接抗人球蛋白试验阳性血清学检测分析[J].细胞与分子免疫学杂志,2022,38(12):1127-1128.
[14]	张联博,李欣,田勇.自身免疫性溶血性贫血输血治疗方案回顾性分析[J].哈尔滨医科大学学报,2022,56(1):76-79.
[15]	陈麟凤,庄健美,张金荣.直接抗人球蛋白试验阳性强度对患者红细胞输注效果的影响[J].中华医学杂志,2020,100(44) :3510-3514.
[16]	郝春芬,郑燕蓉.红细胞型不规则抗体分布特点与输血安全[J].武警医学,2014,25(3) :297.
[17]	Zantek N D, Koepsell S A, Tharp D R Jr et al. The direct antiglobulin test:a critical step in the evaluation of hemolysis[J]. Am J Hematol, 2012,87(7):707-709.